Claims for Patent: 11,911,518

Summary for Patent: 11,911,518

Title:	Compositions for treatment of attention deficit hyperactivity disorder
Abstract:	Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
Inventor(s):	David Lickrish, Feng Zhang
Assignee:	Ironshore Pharmaceuticals and Development Inc Cayman Island , Formulation Technologies LLC
Application Number:	US17/557,524
Patent Claims:	1. A method of treating a pediatric or adolescent subject having Attention Deficit Hyperactivity Disorder (ADHD), comprising: orally administering a solid, oral pharmaceutical composition comprising a plurality of particles, each of the particles comprising: a core comprising an effective amount of methylphenidate or a pharmaceutical salt thereof; a sustained release layer; and a delayed release layer; wherein the composition comprising the plurality of particles provides at least a 6 hour lag time during which the composition releases no more than 5% of the total methylphenidate or a pharmaceutical salt thereof followed by a sustained release period with a median Tmax of about 12-16 hours when administered to healthy adults. 2. The method of claim 1, wherein the composition provides at least an 8 hour lag time during which the composition releases no more than about 5% of the total methylphenidate or a pharmaceutical salt thereof. 3. The method of claim 1, wherein the composition provides at least a 10 hour lag time during which the composition releases no more than 10% of the total methylphenidate methylphenidate or a pharmaceutical salt thereof. 4. The method of claim 1, wherein the composition is contained in a capsule. 5. The method of claim 1, wherein: the administering is in the evening; and the method provides the pediatric or adolescent subjects having Attention Deficit Hyperactivity Disorder (ADHD) with a significant improvement compared to a placebo in Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale (SKAMP) combined scores for a period from about 11 hours through about 23 hours after the administering in the evening. 6. The method of claim 1, wherein: the administering is in the evening; and the method provides pediatric or adolescent subjects having Attention Deficit Hyperactivity Disorder (ADHD) with a significant improvement compared to a placebo in ADHD Rating Scale (ADHD-RS-IV) Total Score, Before School Functioning Questionnaire (BSFQ) score, and/or Parent Rating of Evening and Morning Behavior-Revised (PREMB-R AM) score. 7. The method of claim 1, wherein the effective amount methylphenidate or a pharmaceutical salt thereof is 20 mg, 40 mg, 60 mg, 80 mg or 100 mg. 8. The method of claim 1, wherein, following the lag time, the remaining methylphenidate or a pharmaceutical salt thereof that is released from the composition is released during the sustained release period.